They found no difference in this marker in the serum of prostate cancer patients compared to BPH controls [41] or showed an increase in P-selectin in the palliative group and a decrease in the group with locally advanced cancer undergoing surgery [8]. The gene discussed is SELP; the disease is benign prostatic hyperplasia.